 rais pt
reiter buy rais pt base significantli improv
earn profil next year posit enbrel outcom remov
binari risk think investor come around own stock
move higher see pe expans new blockbust pot come
next year ep compound-annual-growth-rate vs consensu quit simpli
math pe ep
met w/ management week reiter posit view stock think
move higher base remov binari enbrel risk new valu creation
pipelin drug come acceler earn profil next year
previous wrote note street cautiou enbrel biosimilar risk kept
investor away stock posit outcom remov binari
risk think investor come around own pipelin
come blockbust data next month includ kra
lung colorect data combo data phase ii bcma long-
act myeloma data earli phase tezepelumab asthma data
drug could add revenu meaning off-set known modest
base biz eros go flat revenu profil low-singl
digit revenu growth year ep compound-annual-growth-rate acceler
plu dividend yield gener total return addit bought
otezla celg/bmi could ep accret base math
predict street see increment posit given littl credit capit
meet w/ management think co posit increas visibl earn
durabl post-enbrel decis notabl grow pipelin includ kra
henc think street start appreci develop new detail
dcf pipelin model incorpor drug kra bcma tezepelumab bi-
specif etc could add peak revenu contact us refin
model drug start contribut revenu time-frame
allow revenu growth low-singl digit vs flat/down ep grow
see pipelin catalyst next mo kra lung cancer data
world lung well pot colorect cancer data esmo bcma updat
oppti bcma extend half-lif tezepelumab
oppti phase asthma data phase i/ii oncology/bit program
oppti initi phase data includ
bite all/nhl aml egfr bite gbm bottom
line program could drive ep growth medium-term help expand
multipl closer toward view
separ could make bid otezla think possibl see insid
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
price target base appli
multipl ep
view lower-risk lower-beta higher
visibl biotech move higher benefit
biotech sector see posit rotat
believ consensu estim gener low
next year
upsid scenario price base appli
multipl non-gaap ep
impact neulasta biosimilar launch less
expect onpro devic maintain market share
high visibl largest drug enbrel
sale acceler us/eu
continu better-than-anticip launch aimovig
kra play significantli faster
migrain
better expect
posit tezepelumab data
downsid scenario price base
appli multipl non-gaap ep
greater-than-anticip competit mylan
unfavor legal develop samsung/
sandoz enbrel biosimilar
higher expect price pressur enbrel
slower expect sale reimburs
aimovig launch trajectori neg affect
disappoint kra upcom
kra oncolog program could surpris upsid
bite t-cell engag platform garner attent
next month w/ new data releas
see potenti balanc sheet deploy
aimovig launch trajectori continu strong
believ repatha continu see volum growth
new ndc decreas script abandon rate
think eros entranc neulasta
biosimilar may over-st
updat clinic data kra program oncolog
phase tezepelumab asthma data
new bcma data prove compet
celg
bolt-on larg hedg biosimilar
risk add emerg market exposur
continu strong aimovig growth/launch trajectori
pleas see import disclosur inform page report
could buy otezla continu front page
recent reiter continu take disciplin approach
look opportun state area therapeut interest includ
clinic even commerci asset known expertis area view
enbrel litig play favor compani could tempt build
inflamm franchis greater visibl cash flow come
next year though debat
sinc bmy/celg need divest otezla psoriasi drug deal close
seller market could enabl acquir drug perhap
sale think investor street bogey perceiv
cheap versu necessarili cheap deal make sens us would put
portion cash balanc good use gener posit roi
year thu accret medium-term especi sinc otezla patent
expir addit would forese less ftc issu compar major
player sinc oral numer psoriasi drug
pleas see import disclosur inform page report
fiscal year end decemb growth rate total equiti research
attent shift toward kra data
full preview note contact us kra market model world lung
expect updat lung data oral session show
longer durat addit month follow-up initi respond
 go april perhap late juli cutoff treatment durat could extend
week week month
continu solid respons rate orr high dose come anywher
logic come perfect perhap
co specif mani pt estimate perhap surpris see
perhap anoth cr sinc note patient cr week post april
esmo could present colorect solid tumor data includ
addit month follow-up initi stable-diseas patient
mean treatment durat could similarli extend week robust
week month though note stabl diseas necessarili impress patient
high-dos cohort increas patient patient drive orr
perhap think anyth higher would constru
posit like lead plan pivot studi know
happen yet think talk respons alreadi ep call
 probabl confid
remind acquir bite platform micromet
follow leverag technolog bring blincyto develop
fda approv creat sever bite antibodi improv core technolog
bispecif t-cell engag bite antibodi type bispecif antibodi
develop treatment variou cancer bite design engag
two differ target simultan name t-cell cancer cell bispecif
antibodi creat link variabl domain two antibodi one arm
specif surfac t-cell arm specif protein found
primarili tumor cell bcma engag arm target
caus t-cell within rang cancer cell t-cell mediat destruct
new half-lif extend bite improv commerci profil
origin bite construct short half-lif hour partial due small
size absenc fc region short half-lif bitter-sweet allow
quick elimination/reduct cytotox mar necessit continu iv
infus half-lif extend hle bite ad fc domain extend
half-lif day addit longer half-lif new construct may also provid greater
pleas see import disclosur inform page report
efficaci yet see clinic data hle bite candid
hle bite drug candid clinic trial advanc program
expect present initi clinic data medic meet
bcma bite program multipl myeloma proof concept work
least similar car-t key program move forward
current two bcma bite antibodi clinic develop
antibodi vari mere type bite gener use
first-gener bite hle bite
recent confer initi data phase dose escal studi
multipl myeloma patient present
orr achiev mrd neg cr key dose
g/day
data least similar car-t includ celg/blu although
cross-trial comparison nuanc around patient less prior line
therapi prior line altern one might say car-t also slightli
select healthier less frail pt due fact need abl surviv day w/
major progress order wait drug manufactur
april mdor month rang month phase
ib/ii trial underway
pleas see import disclosur inform page report
long-act version current undergo dose escal trial
initi data expect though yet see in-human data pre-clin data
bode well treat monkey demonstr dose-depend reduct
compani plan ultim priorit either advanc
molecul gener enough data comfort choos strongli
predict like move forward potent dose given much
collabor celg develop bcma car-t treatment multipl
myeloma similar work first second gener drug
candid respect advanc candid
robust data high dose cell exhibit mdor month
date bite car-t bcma program exhibit solid efficaci profil high
respons rate key differenti like still determin
platform furthermor platform second gener product may
extend durabl look forward data second-gen bcma bite
present
pleas see import disclosur inform page report
world lung next orr great
abstract releas probabl wont
interest sinc submiss like back april
expect updat lung data oral session show
addit month follow-up initi respond go
april perhap late juli cutoff treatment durat could extend week
week month
orr high dose come anywher logic come
perfect perhap co specif mani pt
estimate perhap also surpris see coupl sinc
note patient cr week post april data cutoff
earli relaps drug resist ultim think month durat
respons patient would meaning chemo low respons
durabl
remind old april cutoff patient achiev orr
includ high-dos
follow open dose-expans complet patient
enrol juli take month enrol
believ expans phase evalu high-dos includ
mix nsclc solid tumor appendic patient
exhibit nsclc data
esmo confirm poster
esmo poster entitl
phase studi novel molecul target
think poster provid data lung cancer includ colorect
appendic tumor cohort obvious see least respons
colorect appendic consist w/ management alreadi disclos ep
call current investor know respond high
dose perhap orr quit good tough cancer
view inde key data focu high dose cohort
pleas see import disclosur inform page report
